Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple Myeloma
Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.
Faiz Anwer, MD, oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig CancerInstituteof Cleveland Clinic; a member of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center; and an associate professor in the Department of Medicine at the School of Medicine at Case Western Reserve University, discusses the efficacy of CAR T-cell therapy in multiple myeloma.
CAR T-cell therapy has demonstrated some unique advantages over other available treatmentsfor patients withmultiple myeloma, says Anwer. One of these advantages is the matter of targeted specificity, which has been observed in numerous monoclonal antibodies. There is also an advantage in the cytotoxicity of a CAR T-cell–based therapy.
This combination of specificity and cytotoxicity has resulted in very high objective response rates in this patient population, Anwer concluded.
